Symbols

Symbols

VTRS

VTRS

Viatris Raises Guidance and Boosts Capital Returns Amid Ongoing Challenges.

Thursday Nov 06, 2025

Viatris to Host Investor Event in Q1 2026 to Discuss Cost Savings and Innovation Strategy

Viatris Q3 Earnings Top Estimates, Revenue Down 2% YOY

Global Needle-Free Devices Market to Reach $27.7 Billion by 2030, Growing at a CAGR of 10.2% from 2025

Viatris Q3 Adj. Net Income Down, Updates 2025 Guidance

Viatris Q3 revenue meets expectations, raises 2025 guidance ranges.

Viatris Q3 growth rate slows across product categories and regions sequentially.

Viatris Q3 revenue in line, raises 2025 guidance.

Wednesday Nov 05, 2025

Major Earnings Ahead: Viatris, Moderna, ConocoPhillips, Datadog, AstraZeneca, and Others to Report Thursday Morning

Viatris Q3 Earnings Preview: Debt, Pipeline Performance in Focus Amid Stock Slump

Bitcoin Price Forecast: Arthur Hayes Predicts $1 Million by 2028

Tuesday Nov 04, 2025

Viatris: Breaking Down Barriers to Access and Building Resilient Health Systems

Viatris Inc. Announces Quarterly Dividend and ESG Rating Update

Tuesday Oct 28, 2025

Locus Biosciences Partners with Viatris to Develop Precision Antibacterial Therapies for Ophthalmic Infections

Tuesday Oct 21, 2025

Viatris Inc. Completes Acquisition of Aculys Pharma, Gains Rights to Pitolisant and Spydia

Thursday Oct 16, 2025

Viatris Expands Neurology Portfolio in Japan through Acquisition of Aculys Pharma

Wednesday Oct 15, 2025

Viatris Expands CNS Portfolio in Japan with Aculys Pharma Acquisition

Truist Securities initiates Viatris coverage on Buy, sets PT at $15.

Monday Oct 13, 2025

Viatris to Participate in UBS and Jefferies Healthcare Conferences.

Viatris to Participate in UBS Global Healthcare Conference and Jefferies Global Healthcare Conference